The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patientsMatthew Kennedy, Mark S. Forman, Michael Tanen et al.|Science Translational Medicine|2016Cited by 416
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s DiseaseJack D. Scott, Andrew W. Stamford, Sarah W. Li et al.|Journal of Medicinal Chemistry|2016Cited by 165
Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitorJared N. Cumming, Andrew W. Stamford, Elizabeth M. Smith et al.|Bioorganic & Medicinal Chemistry Letters|2012Cited by 153
Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and DepressionRobert A. Hodgson, John C. Hunter, Rosalia Bertorelli et al.|Journal of Pharmacology and Experimental Therapeutics|2009Cited by 149
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D. Scott, Michael W. Miller, Duane E. DeMong et al.|Journal of Medicinal Chemistry|2017Cited by 147